Identification of polyphenolic compounds and black tea extract as potent inhibitors of lipid membrane destabilization by Aβ42 aggregates

Journal of Alzheimer's Disease

Volumn 27, Issue 4, 2011, Pages 767-779

  Gauci, Alison J ^a   Caruana, Mario ^a   Giese, Armin ^b   Scerri, Charles ^a   Vassallo, Neville ^a  

^a UNIVERSITY OF MALTA   (Malta)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Alzheimer's disease; amyloid ; black tea; liposomes; N benzylidene benzohydrazide; oligomers; polyphenols

Indexed keywords

8 N BENZYLIDENE BENZOHYDRAZIDE; AMYLOID BETA PROTEIN[1-42]; APIGENIN; BAICALEIN; BENZYLIDENE DERIVATIVE; BLACK TEA EXTRACT; FLAVONE; LIPOSOME; OLIGOMER; POLYPHENOL DERIVATIVE; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; DRUG IDENTIFICATION; DRUG STRUCTURE; HUMAN; LIPID MEMBRANE; MEMBRANE DAMAGE; MEMBRANE PERMEABILITY; NONHUMAN; PHOSPHOLIPID MEMBRANE; PRIORITY JOURNAL; PROTEIN AGGREGATION;

EID: 82955223925     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-111061     Document Type: Article

References (74)

1. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimers disease. Lancet 377, 1019-1031
2. Ritchie K, Lovestone S (2002) The dementias. Lancet 360, 1759-1766 (Pubitemid 35447916)
3. Crews L, Masliah E (2010) Molecular mechanisms of neurodegeneration in Alzheimers disease. Hum Mol Genet 19, R12-R20
4. Hardy J (2009) The amyloid hypothesis for Alzheimers disease: A critical reappraisal. J Neurochem 110, 1129-1134
5. Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, Aimoto S, Elliott JI, Van Nostrand WE, Smith SO (2010) Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat Struct Mol Biol 17, 561-567
6. Perl DP (2000) Neuropathology of Alzheimers disease and related disorders. Neurol Clin 18, 847-864 (Pubitemid 32042599)
7. Luheshi LM, Tartaglia GG, Brorsson AC, Pawar AP, Watson IE, Chiti F, Vendruscolo M, Lomas DA, Dobson CM, Crowther DC (2007) Systematic in vivo analysis of the intrinsic determinants of amyloid Beta pathogenicity. PLoS Biol 5, e290
8. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (Pubitemid 34288854)
9. Walsh DM, Selkoe DJ (2004) Oligomers on the brain: The emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 11, 213-228 (Pubitemid 38689025)
10. Selkoe DJ (2008) Soluble oligomers of the amyloid betaprotein impair synaptic plasticity and behavior. Behav Brain Res 192, 106-113
11. Takamura A, Okamoto Y, Kawarabayashi T, Yokoseki T, Shibata M, Mouri A, Nabeshima T, Sun H, Abe K, Urisu T, Yamamoto N, Shoji M, Yanagisawa K, Michikawa M, Matsubara E (2011) Extracellular and intraneuronal HMWAbetaOs represent a molecular basis of memory loss in Alzheimers disease model mouse. Mol Neurodegene 6, 20
12. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8, 79-84 (Pubitemid 41236735)
13. ReedMN,Hofmeister JJ, Jungbauer L,WelzelAT,YuC, Sherman MA, Lesne S, Ladu MJ, Walsh DM, Ashe KH, Cleary JP (2011) Cognitive effects of cell-derived and synthetically derived Abeta oligomers. Neurobiol Aging 32, 1784-1794
14. Kokubo H, Kayed R, Glabe CG, Staufenbiel M, Saido TC, Iwata N,YamaguchiH(2009) Amyloid beta annular protofibrils in cell processes and synapses accumulate with aging and Alzheimer-associated genetic modification. Int J Alzheimers Dis pii: 689285, 1-7
15. Eckert GP, Wood WG, Muller WE (2010) Lipid membranes and beta-amyloid: A harmful connection. Curr Protein Pept Sci 11, 319-325
16. Kremer JJ, Sklansky DJ, Murphy RM (2001) Profile of changes in lipid bilayer structure caused by beta-amyloid peptide. Biochemistry 40, 8563-8571 (Pubitemid 32667263)
17. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, GlabeCG(2004) Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 279, 46363-46366 (Pubitemid 39518276)
18. de Planque MR, Raussens V, Contera SA, Rijkers DT, Liskamp RM, Ruysschaert JM, Ryan JF, Separovic F, Watts A (2007) Beta-Sheet structured beta-amyloid(1-40) perturbs phosphatidylcholine model membranes. J Mol Biol 368, 982-997 (Pubitemid 46574660)
19. Davis CH, Berkowitz ML (2009) Interaction between amyloid-beta (1-42) peptide and phospholipid bilayers: A molecular dynamics study. Biophys J 96, 785-797
20. 2+ channels provides a mechanism for neuronal death in Alzheimers disease. Ann N Y Acad Sci 747, 256-266
21. Lin H, Bhatia R, Lal R (2001) Amyloid beta protein forms ion channels: Implications for Alzheimers disease pathophysiology. FASEB J 15, 2433-2444 (Pubitemid 33063171)
22. Arispe N, Diaz JC, Simakova O (2007) Abeta ion channels. Prospects for treating Alzheimers disease with Abeta channel blockers. Biochim Biophys Acta 1768, 1952-1965 (Pubitemid 47125852)
23. Kawahara M (2010) Neurotoxicity of beta-amyloid protein: Oligomerization, channel formation, and calcium dyshomeostasis. Curr Pharm Des 16, 2779-2789
24. Kawahara M, Ohtsuka I, Yokoyama S, Kato-Negishi M, Sadakane Y (2011) Membrane incorporation, channel formation, and disruption of calcium homeostasis by Alzheimers beta-amyloid protein. Int J Alzheimers Dis 2011, 304583
25. Simakova O, Arispe NJ (2007) The cell-selective neurotoxicity of the Alzheimers Abeta peptide is determined by surface phosphatidylserine and cytosolicATP levels. Membrane binding is required for Abeta toxicity. J Neurosci 27, 13719-13729 (Pubitemid 350278273)
26. Hung LW, Ciccotosto GD, Giannakis E, Tew DJ, Perez K, Masters CL, Cappai R, Wade JD, Barnham KJ (2008) Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity. J Neurosci 28, 11950-11958
27. Diaz JC, Simakova O, Jacobson KA, Arispe N, Pollard HB (2009) Small molecule blockers of the Alzheimer Abeta calcium channel potently protect neurons from Abeta cytotoxicity. Proc Natl Acad Sci U S A 106, 3348-3353
28. Sepulveda FJ, Parodi J, Peoples RW, Opazo C, Aguayo LG (2010) Synaptotoxicity of Alzheimer beta amyloid can be explained by its membrane perforating property. PLoS One 5, e11820
29. Kostka M, Hogen T, Danzer KM, Levin J, Habeck M, Wirth A, Wagner R, Glabe CG, Finger S, Heinzelmann U, Garidel P, Duan W, Ross CA, Kretzschmar H, Giese A (2008) Single particle characterization of iron-induced poreforming alpha-synuclein oligomers. J Biol Chem 283, 10992-11003
30. Bastianetto S, Krantic S, Quirion R (2008) Polyphenols as potential inhibitors of amyloid aggregation and toxicity: Possible significance to Alzheimers disease. Mini Rev Med Chem 8, 429-435
31. Lemkul JA, Bevan DR (2010) Destabilizing Alzheimers Abeta(42) protofibrils with morin: Mechanistic insights from molecular dynamics simulations. Biochemistry 49, 3935-3946
32. Thapa A, Woo ER, Chi EY, Sharoar MG, Jin HG, Shin SY, Park IS (2011) Biflavonoids are superior to monoflavonoids in inhibiting amyloid-beta toxicity and fibrillogenesis via accumulation of nontoxic oligomer-like structures. Biochemistry 50, 2445-2455
33. Caruana M, Hogen T, Levin J, Hillmer A, Giese A, Vassallo N (2011) Inhibition and disaggregation of alpha-synuclein oligomers by natural polyphenolic compounds. FEBS Lett 585, 1113-1120
34. Manach C, Scalbert A, Morand C, Remesy C, Jimenez L (2004) Polyphenols: Food sources and bioavailability. Am J Clin Nutr 79, 727-747 (Pubitemid 41103873)
35. Scalbert A,Williamson G (2000) Dietary intake and bioavailability of polyphenols. J Nutr 130, 2073S-2085S (Pubitemid 30619386)
36. Quideau S, Deffieux D, Douat-Casassus C, PouyseguL(2011) Plant polyphenols: Chemical properties, biological activities, and synthesis. Angew Chem Int Ed Engl 50, 586-621
37. Oteiza PI, Erlejman AG, Verstraeten SV, Keen CL, Fraga CG (2005) Flavonoid-membrane interactions: A protective role of flavonoids at the membrane surface? Clin Dev Immunol 12, 19-25 (Pubitemid 41647026)
38. Ollila F, Halling K, Vuorela P, Vuorela H, Slotte JP (2002) Characterization of flavonoid-biomembrane interactions. Arch Biochem Biophys 399, 103-108 (Pubitemid 34848316)
39. Arora A, Byrem TM, Nair MG, Strasburg GM (2000) Modulation of liposomal membrane fluidity by flavonoids and isoflavonoids. Arch Biochem Biophys 373, 102-109 (Pubitemid 30046494)
40. Tedeschi A, DErrico G, Lauro MR, Sansone F, Di Marino S, DUrsi AM, Aquino RP (2010) Effect of flavonoids on the Abeta(25-35)-phospholipid bilayers interaction. Eur J Med Chem 45, 3998-4003
41. Rezai-Zadeh K, Arendash GW, Hou H, Fernandez F, Jensen M, Runfeldt M, Shytle RD, Tan J (2008) Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res 1214, 177-187
42. Wang J, Ho L, Zhao W, Ono K, Rosensweig C, Chen L, Humala N, Teplow DB, Pasinetti GM (2008) Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimers disease. J Neurosci 28, 6388-6392
43. Ho L, Chen LH,Wang J, ZhaoW, Talcott ST, Ono K, Teplow D, Humala N, Cheng A, Percival SS, Ferruzzi M, Janle E, Dickstein DL, PasinettiGM(2009) Heterogeneity in red wine polyphenolic contents differentially influences Alzheimers disease-type neuropathology and cognitive deterioration. J Alzheimers Dis 16, 59-72
44. Hamaguchi T, Ono K, Murase A, YamadaM(2009) Phenolic compounds prevent Alzheimers pathology through different effects on the amyloid-beta aggregation pathway. Am J Pathol 175, 2557-2565
45. Parachikova A, Green KN, Hendrix C, LaFerla FM (2010) Formulation of a medical food cocktail for Alzheimers disease: Beneficial effects on cognition and neuropathology in a mouse model of the disease. PLoS One 5, e14015
46. Meydani M (2001) Nutrition interventions in aging and ageassociated disease. Ann N Y Acad Sci 928, 226-235 (Pubitemid 32386084)
47. Bastianetto S, Quirion R (2002) Natural extracts as possible protective agents of brain aging. Neurobiol Aging 23, 891-897 (Pubitemid 35217714)
48. Kim J, Lee HJ, Lee KW (2010) Naturally occurring phytochemicals for the prevention of Alzheimers disease. J Neurochem 112, 1415-1430
49. Necula M, Kayed R, Milton S, Glabe CG (2007) Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem 282, 10311-10324 (Pubitemid 47093410)
50. El-Agnaf OM, Paleologou KE, Greer B, Abogrein AM, King JE, Salem SA, Fullwood NJ, Benson FE, Hewitt R, Ford KJ, Martin FL, Harriott P, Cookson MR, Allsop D (2004) A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinsons disease and related disorders. FASEB J 18, 1315-1317 (Pubitemid 39561588)
51. Takamori S, Holt M, Stenius K, Lemke EA, Gronborg M, Riedel D, Urlaub H, Schenck S, Brugger B, Ringler P, Muller SA, Rammner B, Grater F, Hub JS, De Groot BL, Mieskes G, Moriyama Y, Klingauf J, Grubmuller H, Heuser J,Wieland F, Jahn R (2006) Molecular anatomy of a trafficking organelle. Cell 127, 831-846 (Pubitemid 44716256)
52. Blau L,Weissmann G (1988) Transmembrane calcium movements mediated by ionomycin and phosphatidate in liposomes with Fura 2 entrapped. Biochemistry 27, 5661-5666
53. Naiki H, Gejyo F (1999) Kinetic analysis of amyloid fibril formation. Methods Enzymol 309, 305-318 (Pubitemid 29446457)
54. Hortschansky P, Schroeckh V, Christopeit T, Zandomeneghi G, Fandrich M (2005) The aggregation kinetics of Alzheimers beta-amyloid peptide is controlled by stochastic nucleation. Protein Sci 14, 1753-1759 (Pubitemid 40994145)
55. Cizas P, Budvytyte R, Morkuniene R, Moldovan R, Broccio M, Losche M, Niaura G,Valincius G, BorutaiteV(2010) Sizedependent neurotoxicity of beta-amyloid oligomers. Arch Biochem Biophys 496, 84-92
56. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG (2005) Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 280, 17294-17300 (Pubitemid 41389198)
57. Sokolov Y, Kozak JA, Kayed R, Chanturiya A, Glabe C, Hall JE (2006) Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J Gen Physiol 128, 637-647 (Pubitemid 44833376)
58. Valincius G, Heinrich F, Budvytyte R, Vanderah DJ, McGillivray DJ, SokolovY, Hall JE, LoscheM(2008) Soluble amyloid beta-oligomers affect dielectric membrane properties by bilayer insertion and domain formation: Implications for cell toxicity. Biophys J 95, 4845-4861
59. Schauerte JA,Wong PT,Wisser KC, Ding H, Steel DG, Gafni A (2010) Simultaneous single-molecule fluorescence and conductivity studies reveal distinct classes of Abeta species on lipid bilayers. Biochemistry 49, 3031-3039
60. Nag S, Chen J, Irudayaraj J, Maiti S (2010) Measurement of the attachment and assembly of small amyloid-beta oligomers on live cell membranes at physiological concentrations using single-molecule tools. Biophys J 99, 1969-1975
61. Kayed R, Pensalfini A, Margol L, Sokolov Y, Sarsoza F, Head E, Hall J, Glabe C (2009) Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem 284, 4230-4237
62. Alarcon JM, Brito JA, Hermosilla T, Atwater I, Mears D, Rojas E (2006) Ion channel formation by Alzheimers disease amyloid beta-peptide (Abeta40) in unilamellar liposomes is determined by anionic phospholipids. Peptides 27, 95-104 (Pubitemid 43061042)
63. Inoue S (2008) In situ Abeta pores in AD brain are cylindrical assembly of Abeta protofilaments. Amyloid 15, 223-233
64. Yoshiike Y, Kayed R, Milton SC, Takashima A, Glabe CG (2007) Pore-forming proteins share structural and functional homology with amyloid oligomers. Neuromolecular Med 9, 270-275 (Pubitemid 350129702)
65. Mandel SA, Amit T, Weinreb O, Youdim MB (2011) Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and neurodegenerative diseases. J Alzheimers Dis 25, 187-208
66. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M (2003) Potent anti-amyloidogenic and fibrildestabilizing effects of polyphenols in vitro: Implications for the prevention and therapeutics of Alzheimers disease. J Neurochem 87, 172-181 (Pubitemid 37210651)
67. Ono K, Hasegawa K, Naiki H, Yamada M (2004) Antiamyloidogenic activity of tannic acid and its activity to destabilize Alzheimers beta-amyloid fibrils in vitro. Biochim Biophys Acta 1690, 193-202 (Pubitemid 39423614)
68. Porat Y, Abramowitz A, Gazit E (2006) Inhibition of amyloid fibril formation by polyphenols: Structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 67, 27-37 (Pubitemid 43881385)
69. Re F, Airoldi C, Zona C, Masserini M, La Ferla B, Quattrocchi N, Nicotra F (2010) Beta amyloid aggregation inhibitors: Small molecules as candidate drugs for therapy of Alzheimers disease. Curr Med Chem 17, 2990-3006
70. Reza AA, Ladiwala AR, Dordick JS, Tessier PM (2011) Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways. J Biol Chem 286, 3209-3218
71. Bertsch U,Winklhofer KF, Hirschberger T, Bieschke J,Weber P, Hartl FU, Tavan P, Tatzelt J, Kretzschmar HA, Giese A (2005) Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets. J Virol 79, 7785-7791 (Pubitemid 40756812)
72. Schiffer NW, Broadley SA, Hirschberger T, Tavan P, Kretzschmar HA, Giese A, Haass C, Hartl FU, Schmid B (2007) Identification of anti-prion compounds as efficient inhibitors of polyglutamine protein aggregation in a zebrafish model. J Biol Chem 282, 9195-9203 (Pubitemid 47093482)
73. Hillmer AS, Putcha P, Levin J, Hogen T, Hyman BT, Kretzschmar H, McLean PJ, Giese A (2010) Converse modulation of toxic alpha-synuclein oligomers in living cells by N′-benzylidene-benzohydrazide derivates and ferric iron. Biochem Biophys Res Commun 391, 461-466
74. Newman DJ, Cragg GM (2009) Natural product scaffolds as leads to drugs. Future Med Chem 1, 1415-1427